Feature | November 04, 2013

Genetic Profiling May Provide Clinical Benefit by Identifying Heart Attack Patients Resistant to Blood Thinners

Results of the GIANT Trial Reported at TCT 2013

cath lab cardiac diagnostics genetic testing antiplatelet therapy blood monitors
November 4, 2013 — According to a new study, genetic profiling of patients undergoing percutaneous coronary intervention (PCI) may help cardiology teams adjust treatment and improve ischemic outcomes for patients who do not properly metabolize thienopyridine blood thinning therapies such as clopidogrel.
Findings from the GIANT trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).
The GIANT trial evaluated the clinical impact of CYP2C19 genetic profiling and compliance to an adjusted thienopyridine treatment. The primary endpoint was a composite of death, myocardial infarction and stent thrombosis after one year in slow responder patients with appropriate therapy after genotyping, compared to non-slow responders. 
The prospective, multicenter, single-arm study enrolled 1,499 patients at the time of primary PCI (onset chest pain < 24 hours). Genetic profiling was performed within 48 hours after intervention to detect a loss of CYP2C19 gene function and identify a resistance to clopidogrel. Strong recommendations for treatment adjustment were sent to investigators when patients were identified as slow responders. 
Dual antiplatelet therapy (DAPT) was prescribed for 12 months after PCI and one-year follow up was performed in 96.4 percent of patients (n = 1,445) including objective assessment of compliance. A total of 22 percent of patients (n = 319) had a profile associated with a CYP2C19 loss of function, known as the slow responder group. The remaining patients constituted the control group.
In the slow responder group, 85 percent received an adjusted thienopyridine regimen after the release of the genetic profile. Within the slow responder group, the patients who received adjusted therapy experienced fewer adverse events compared to those who did not receive adjusted therapy (3.3 percent versus 15.6 percent, respectively) after one year. Further, the patients who received adjusted therapy experienced a similar rate of adverse events as the control group (3.3 percent versus 3.04 percent). Poor compliance to treatment was objectively identified in 4.9 percent of patients at one year, and those patients experienced numerically more ischemic events.
“Results from the GIANT trial suggest that in patients with acute myocardial infarction treated with primary PCI, identification of a slow response to clopidogrel with subsequent adjustment of treatment leads to similar one year major ischemic event rates to patients with a favorable genetic profile to clopidogrel response,” said Bernard Chevalier, M.D., L'Institut CardioVasculaire Paris-Sud in Massy, Francem and lead investigator of the trial. “These findings may help determine alternative treatment strategies for patients identified as CYP2C19 poor metabolizers.” 
The GIANT trial was funded by Biotronik. Chevalier reported receiving research grants/speaker fees or being a consultant for Abbott Vascular, Asahi, Astra Zeneca, AVI, Boston Scientific, Biotronik, Colibri, Cook, Cordis, Daichi-Sankyo, Eli-Lilly, Iroko, Medtronic and Terumo. He is also currently a minor shareholder and director of CERC, a clinical research organization.
For more information: www.crf.org

Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
News | Blood Testing | March 22, 2016
March 22, 2016 — Critical Diagnostics announced that it entered into a license agreement for the exclusive worldwide
Overlay Init